Kymera Therapeutics (NASDAQ:KYMR) Receives "Buy" Rating from Truist Financial

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at Truist Financial in a note issued to investors on Friday, Benzinga reports. They presently have a $53.00 target price on the stock, down from their previous target price of $54.00. Truist Financial's target price points to a potential upside of 14.05% from the stock's current price.

A number of other equities analysts also recently commented on the company. Leerink Partnrs upgraded Kymera Therapeutics to a "strong-buy" rating in a research report on Monday, September 9th. Leerink Partners reissued an "outperform" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Monday, September 9th. Wells Fargo & Company raised their price objective on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an "equal weight" rating in a research report on Monday, August 12th. Wolfe Research upgraded shares of Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 target price on the stock in a report on Monday, August 26th. Finally, Oppenheimer raised their price target on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an "outperform" rating in a report on Friday, September 27th. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $49.15.

Kymera Therapeutics Trading Up 0.6 %

KYMR traded up $0.30 on Friday, hitting $46.47. 432,609 shares of the company's stock were exchanged, compared to its average volume of 597,398. The firm has a 50-day moving average price of $47.06 and a 200-day moving average price of $40.57. The stock has a market cap of $2.87 billion, a price-to-earnings ratio of -19.02 and a beta of 2.21. Kymera Therapeutics has a fifty-two week low of $9.60 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The company had revenue of $3.74 million during the quarter, compared to analysts' expectations of $10.34 million. During the same quarter in the prior year, the company earned ($0.90) EPS. Kymera Therapeutics's revenue was down 20.9% compared to the same quarter last year. On average, equities analysts predict that Kymera Therapeutics will post -2.85 EPS for the current year.

Insider Activity

In related news, Director Pamela Esposito sold 13,500 shares of the company's stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Pamela Esposito sold 13,500 shares of the stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. Company insiders own 15.82% of the company's stock.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Values First Advisors Inc. acquired a new stake in shares of Kymera Therapeutics during the third quarter worth about $61,000. Mirae Asset Global Investments Co. Ltd. increased its position in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock worth $114,000 after buying an additional 504 shares during the period. Comerica Bank lifted its stake in Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company's stock valued at $134,000 after buying an additional 400 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in shares of Kymera Therapeutics in the second quarter valued at approximately $139,000. Finally, Quest Partners LLC grew its position in shares of Kymera Therapeutics by 1,402.0% during the second quarter. Quest Partners LLC now owns 5,212 shares of the company's stock worth $156,000 after acquiring an additional 4,865 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.